The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
American Commercial Lines
Advised American Commercial Lines, an operator of barges, towboats and shipyards, on its out of court restructuring
Completel Europe NV
Advised Completel, an alternative telecom operator, on a balance sheet restructuring and recapitalisation agreement involving an exchange offer for €255 million in face value of public bonds (debt/equity swap), €30 million in new capital from two major shareholders and €8 million from certain bondholders
Morton’s Restaurant Group Inc.
Advised the Special Committee of Morton’s on sale of the Company.
Bethlehem Steel Corporation
Advised Bethlehem Steel Corp., the United States third largest steel producer, in connection with its Chapter 11 proceedings and eventual sale to International Steel
Regal Cinemas, Inc.
Advised Regal Cinemas, the largest theatre chain in the United States, on its prepackaged bankruptcy plan and acquisition by The Anschutz Corporation
RCN Corporation
Advised RCN, the nation’s largest cable overbuilder, in a tender offer for up to $1.1 billion in face value of public indebtedness
Sterling Chemicals
Advised Sterling Chemicals in connection with its Chapter 11 proceedings
AMRESCO
Advised AMRESCO, a specialty finance company, on its sale to NCSI pursuant to Section 363 of the Bankruptcy Code
US Office Products Company
Advised the Official Committee of Unsecured Creditors in connection with the Chapter 11 proceedings of US Office Products Company
RBX Corp.
Advised RBX Corp., a leading manufacturer of rubber products in the US, in connection with its Chapter 11 proceedings and financial restructuring
Microsoft Corp.
Retained by the US Justice Department to advise it on the financial implications of the full range of potential remedies in the Microsoft antitrust case (US v. Microsoft).
Genetics Institute
Represented the Special Committee to the Board of Directors of Genetics Institute as AHP exercised its option to acquire the remaining 40% of Genetics Institute